Gastrodin Reversed the Traumatic Stress-induced Depressed-like Symptoms in Rats
Affiliations
Exposure to severe stress can lead to the development of neuropsychiatric disorders such as depression and post-traumatic stress disorder (PTSD) in at-risk individuals. Gastrodin (GAS), a primary constituent of an Oriental herbal medicine, has been shown to effectively treat various mood disorders. Thus, the present study aimed to determine whether GAS would ameliorate stress-associated depression-like behaviors in a rat model of single prolonged stress (SPS)-induced PTSD. Following the SPS procedure, rats received intraperitoneal administration of GAS (20, 50, or 100 mg/kg) once daily for 2 weeks. Subsequently, the rats performed the forced swimming test, and norepinephrine (NE) levels in the hippocampus were measured. Daily GAS (100 mg/kg) significantly reversed depression-like behaviors and restored SPS-induced increases in hippocampal NE concentrations as well as tyrosine hydroxylase expression in the locus coeruleus. Furthermore, the administration of GAS attenuated SPS-induced decreases in the hypothalamic expression of neuropeptide Y and the hippocampal mRNA expression of brain-derived neurotrophic factor. These findings indicate that GAS possesses antidepressant effects in the PTSD and may be an effective herbal preparation for the treatment of PTSD.
Dai Y, Ban W, Yang Z Int J Mol Sci. 2024; 25(17).
PMID: 39273485 PMC: 11394983. DOI: 10.3390/ijms25179540.
Wang S, Yu L, Guo H, Zuo W, Guo Y, Liu H Mol Neurobiol. 2024; 62(1):366-385.
PMID: 38856794 DOI: 10.1007/s12035-024-04267-5.
Gastrodin: a comprehensive pharmacological review.
Wang Y, Bai M, Wang X, Peng Z, Cai C, Xi J Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(6):3781-3802.
PMID: 38165423 DOI: 10.1007/s00210-023-02920-9.
Review on pharmacological effects of gastrodin.
Xiao G, Tang R, Yang N, Chen Y Arch Pharm Res. 2023; 46(9-10):744-770.
PMID: 37749449 DOI: 10.1007/s12272-023-01463-0.
Recent Developments in Protein Lactylation in PTSD and CVD: Novel Strategies and Targets.
Kozlakidis Z, Shi P, Abarbanel G, Klein C, Sfera A BioTech (Basel). 2023; 12(2).
PMID: 37218755 PMC: 10204439. DOI: 10.3390/biotech12020038.